Source: International Congress 2018 – Tests and trends in asthma
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
J. Kang (Shenyang, China), J. Li (Guangzhou, China), L. Kong (Shenyang, China), J. Yang (Beijing, China), L. Wang (Beijing, China), M. Humphries (Beijing, China), I. Kottakis (Basel, Switzerland), R. Fogel (East Hanover, NJ, United States of America), X. Lau (Petaling Jaya, Malaysia), N. Zhong (Guangzhou, China). Relationship between omalizumab efficacy and baseline allergen profile impacts patient-reported outcomes in allergic asthma. 3956

Member's Comments

No comment yet.

Related content which might interest you: Improvements in asthma control and quality of life with omalizumab in allergic (IgE-mediated) asthma patients Source: Annual Congress 2012 - Trials in asthma: asthma exacerbations and severe asthma Year: 2012 Efficacy and safety of ciclesonide in the treatment of patients with persistent allergic or non-allergic asthma Source: Annual Congress 2012 - Asthma treatment: efficacy and safety Year: 2012 Safety and efficacy of omalizumab in children with allergic asthma Source: Annual Congress 2011 - Treating childhood asthma Year: 2011 Dupilumab improves patient-reported outcomes in uncontrolled persistent asthma patients with ongoing allergic rhinitis Source: International Congress 2017 – Asthma and allergy: from the bench to the bedside Year: 2017 Effectiveness of omalizumab in improving quality of life in patients with ‘steroid-resistant‘ asthma and severe allergic rhinitis Source: Annual Congress 2012 - Clinical aspects and treatment of asthma and allergic respiratory diseases Year: 2012 Inflammatory biomarkers in the evaluation of two-year  outcomes  of omalizumab treatment in severe allergic asthma. Source: International Congress 2018 – Biomarkers for evaluating asthma Year: 2018 Assesment of long-term omalizumab treatment in severe allergic asthma Source: Annual Congress 2012 - Asthma: risk factors and effect of anti-IgE Year: 2012 Predictors of response to therapy with omalizumab in patients with severe allergic asthma–a real life study Source: International Congress 2017 – Monitoring asthma control Year: 2017 Variability and lack of predictive ability of asthma end-points in clinical trials Source: Eur Respir J 2002; 20: 1102-1109 Year: 2002 Evaluation and efficacy of allergen immunotherapy in asthma Source: Eur Respir J 2005; 26: Suppl. 49, 399s Year: 2005 Patients’ perception of allergic asthma and their compliance to omalizumab in an Italian clinical setting Source: International Congress 2017 – Asthma management Year: 2017 Treatment and outcomes in patients with asthma and allergic rhinitis Source: Eur Respir J 2005; 26: Suppl. 49, 576s Year: 2005 Improved symptom relief with omalizumab in the treatment of allergic rhinitis Source: Annual Congress 2009 - Severe asthma and its treatment Year: 2009 Impact of omalizumab treatment persistence on asthma control Source: Annual Congress 2012 - Aspects of clinical asthma Year: 2012 Impact of subcutaneous allergoid AIT on patients with allergic rhinitis and/or asthma: A retrospective real-life, long-term cohort analysis Source: Virtual Congress 2020 – Management of allergy, asthma and COPD Year: 2020 Clinical relevance of anti-inflammatory treatment of rhinitis for the course and prognosis of allergic bronchial asthma Source: Annual Congress 2007 - Traditional and novel approaches to assess and achieve asthma control Year: 2007 Real-life effectiveness of omalizumab in patients with severe persistent allergic asthma: the PERSIST study Source: Annual Congress 2009 - Towards improving asthma control Year: 2009 Evaluating the efficacy of omalizumab in severe persistent asthma patients Source: International Congress 2017 – Evolution or revolution in the treatment of asthma and allergies Year: 2017 To assess the effects of combined nasal and inhaled corticosteroid in patients with asthma and persistent allergic rhinitis Source: Annual Congress 2009 - Clinical aspects of inflammatory airways diseases Year: 2009 The anti-IgE antibody omalizumab improves asthma-related quality of life in patients with allergic asthma Source: Eur Respir J 2002; 20: 1088-1094 Year: 2002